Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Innovative Screening Strategy Swiftly Uncovers New Drug Candidates, New Biology

Published: Tuesday, December 24, 2013
Last Updated: Tuesday, December 24, 2013
Bookmark and Share
Method has been utilised to identify compound with promise for obesity-linked diabetes.

Scientists at The Scripps Research Institute (TSRI) have demonstrated a drug-discovery strategy with a double payoff—it enables the rapid selection of chemical compounds that have a desired effect on cells and also highlights how the compounds work.

To illustrate the power of the innovative technique, the TSRI researchers used it to identify a compound that shows promise for treating obesity-linked diabetes. At the same time, they were able to identify the fat-cell enzyme that the compound inhibits—an enzyme that has not yet been a focus of diabetes drug development.

“This integrated strategy we’ve developed has the potential to accelerate the discovery of important biological pathways and may lead to faster development of new drugs for multiple diseases,” said TSRI Associate Professor Enrique Saez.

Saez and his colleague Benjamin F. Cravatt, chair of TSRI’s Department of Chemical Physiology, were the senior authors of the new study, which is reported  December 22, 2013 in an advance online issue of Nature Chemical Biology.

Facilitating Drug Discovery
The new strategy has great potential to streamline drug discovery, a process whose importance to human health can hardly be overemphasized.

Typically, pharmaceutical scientists start the discovery process by “screening” large libraries of chemical compounds in search of one or a few that might treat disease. The dominant strategy of recent decades has been to screen compounds for a specific activity against a known target, for example, inhibiting the function of a certain enzyme thought to be critical for the disease in question. A key advantage of this “target-based” screening is that it uses biochemical tests that can be done relatively simply in a test-tube—or rather, in a large array of tiny test tubes via automated, rapid screening systems that sort through hundreds of thousands of different compounds.

Target-based screening has enabled scientists to discover many useful new drugs, but some wonder whether this basic discovery strategy has already taken all the “low hanging fruit.” In recent years, compounds selected with target-based in vitro tests have seemed to be failing increasingly often when tested in the more realistic biological environments of cells and animals.

An older strategy, “phenotypic” screening, avoids much of this problem by testing compounds for their ability to produce a desired effect directly on living cells. Unfortunately, such cell-based tests often leave open the question of how a useful compound works. “If you don’t know what its relevant molecular target is, then developing that compound into a drug—optimizing its potency, its selectivity, its half-life in the bloodstream and so on—is going to be difficult,” said Saez.

Identifying the molecular targets of compounds selected by phenotypic screens is typically burdensome and time-consuming. But in their new study, Saez, Cravatt and their colleagues were able to speed up the process dramatically. Indeed, their combined phenotypic screening and target-identification approach enabled them to quickly discover, characterize and carry out preclinical tests of a potential new drug for obesity-linked diabetes: a complex metabolic disorder that affects 347 million people worldwide.

A New Diabetes Drug Candidate, Plus Insights into the Disease
The strategy makes use of the increasing availability of special libraries of related compounds that act as inhibitors of entire enzyme classes. In this case, the researchers used a set of compounds, recently synthesized by Cravatt’s laboratory, that tend to inhibit serine hydrolases—a vast enzyme family whose members participate in most biological processes in mammals.

The scientists started with a phenotypic screen, testing their library of compounds for the ability to make young fat cells mature faster and store more fat. Better fat storage means that less fat leaks from fat cells into the liver, muscles and pancreas—a process that frequently occurs with obesity, often interfering with insulin signaling enough to bring on diabetes.

The screen quickly yielded several compounds that had a strong effect in promoting fat-cell fat storage. The researchers then used a method called “activity-based profiling” to identify the fat-cell serine hydrolases that the compounds inhibited most strongly. One of the most potent compounds, WWL113, turned out to work principally by inhibiting Ces3, a serine hydrolase enzyme that scientists have not studied in the context of obesity or diabetes.

The researchers quickly demonstrated WWL113’s effectiveness in two different mouse models of obesity-linked diabetes—one in which the mice are genetically programmed to become obese and diabetic, and another in which normal mice are made obese and diabetic with a high-fat diet. “The treated animals showed resistance to weight gain—they were not putting on as much weight as the controls,” said Saez. “Their blood biochemistry also was getting normalized; their glucose, triglyceride and cholesterol levels were coming down towards normal levels.”

In these mouse tests, WWL113—without any optimization for use as a drug—performed about as well as the FDA-approved diabetes treatment rosiglitazone (Avandia). Notably, the new compound lacked one of the side effects that drugs in rosiglitazone’s class have in mice: the toxic accumulation of lipids in the liver. “Our compound clears lipids from the diabetic mouse liver, whereas rosiglitazone has the opposite effect,” said Saez.

To explore the relevance of these results to humans, the TSRI team worked with collaborating researchers in Australia to test fat samples from obese humans and diabetics. The tests confirmed that the human version of Ces3 also is unusually active in such patients. This suggests that an inhibitor may also work as a diabetes treatment in people.

Saez and his colleagues will next focus on using the new screening strategy to uncover more biological pathways that could yield new mechanisms to develop potential therapies.

Contributors to the study, “Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes,” also included first author Eduardo Dominguez, then a postdoctoral fellow in the Saez Laboratory; as well as TSRI’s Andrea Galmozzi, Jae Won Chang, Ku-Lung Hsu, Joanna Pawlak, Weiwei Li, Cristina Godio, Jason Thomas, David Partida, Sherry Niessen and Daniel K. Nomura; and Australian researchers Paul E. O'Brien and Matthew J. Watt of Monash University, and Aaron P. Russell of Deakin University.

The study was funded in part by the National Institutes for Health (DK081003, DK099810), the American Diabetes Association, The McDonald’s Center for Type 2 Diabetes and Obesity, the National Health and Medical Research Council of Australia, the Hewitt Foundation for Medical Research and the Xunta de Galicia, Spain.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Friday, October 02, 2015
Key Morphine Regulator Identified
The findings could lead to less addictive pain medications.
Thursday, September 24, 2015
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
Thursday, August 06, 2015
Search for Cancer Drug Candidates
Scripps Florida scientists awarded $1.2 million to find drug candidates that could treat a wide range of cancers.
Friday, April 10, 2015
Scripps Florida Scientists Win $1.5 Million Grant to Develop New Cancer Drugs
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded a $1.5 million grant from the National Institutes of Health (NIH) to develop drug candidates that could treat cancer and neurodegenerative disease.
Tuesday, March 24, 2015
Possible Neuron Killing Mechanism Behind Alzheimer’s and Parkinson’s Diseases Discovered
$1.4 million grant will enable team to follow up with search for drug candidates.
Tuesday, February 17, 2015
New Targets and Test to Develop Treatments for Memory Disorders
The study focuses on kinesin, a molecular motor protein that plays a role in the transport of other proteins throughout a cell.
Thursday, November 13, 2014
Chemists Discover Cancer Drug Candidate Structure
Chemists at The Scripps Research Institute have determined the correct structure of a highly promising anticancer compound approved by the U.S. FDA for clinical trials in cancer patients.
Wednesday, May 21, 2014
Scripps Research Institute Creates New Drug Discovery Initiative
Scripps Advance is a new drug discovery initiative to translate early-stage biomedical research projects into clinical development candidates.
Wednesday, April 16, 2014
New Findings from The Scripps Research Institute Could Help Improve Development of Drugs for Addiction
Scientists have described findings that could enable the development of more effective drugs for addiction with fewer side effects.
Thursday, August 08, 2013
Study Reveals How Serotonin Receptors Can Shape Drug Effects from LSD to Migraine Medication
A team of scientists has determined and analyzed the high-resolution atomic structures of two kinds of human serotonin receptor.
Tuesday, March 26, 2013
Discovery of Biological Energy-Sensing Switch Could Have Broad Implications for Biology and Medicine
Biochemists at The Scripps Research Institute (TSRI) have discovered a genetic sequence that can alter its host gene’s activity in response to cellular energy levels.
Tuesday, October 23, 2012
Scripps Research Scientists Create Novel RNA Repair Technology
Discovery could aid search for Huntington’s, Spinocerebellar Ataxia, and Kennedy Disease treatments.
Thursday, January 19, 2012
Scripps Florida Opens its Screening Technology to Florida Scientists
Program invites scientists from Florida universities and other academic research institutions to use screening technologies.
Monday, January 23, 2006
Proteomics Helps in Detecting Breast Cancer Proteins
Proteins, associated with breast cancer, can potentially be used as markers for detection or prevention or as targets for the design of drugs to treat the disease.
Monday, September 12, 2005
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos